Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

February 15, 2017

Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference

February 13, 2017

Relmada Therapeutics to Participate in BIO CEO and Investor Conference

January 25, 2017

Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone

January 24, 2017

Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER

January 5, 2017

Relmada Therapeutics to Present at Biotech Showcase 2017

November 29, 2016

Relmada Therapeutics to Present at LD Micro “Main Event” Investor Conference

October 27, 2016

Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention

October 19, 2016

Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms

October 6, 2016

Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum

September 28, 2016

Relmada Therapeutics’ Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston

«...16 171819 20 21...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top